Yves Toiron

1.0k total citations
21 papers, 823 citations indexed

About

Yves Toiron is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Yves Toiron has authored 21 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Hematology. Recurrent topics in Yves Toiron's work include Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). Yves Toiron is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). Yves Toiron collaborates with scholars based in France, Italy and Canada. Yves Toiron's co-authors include Daniel Birnbaum, F Birg, Sylvie Marchetto, MJ Pébusque, Olivier Rosnet, Cécile Tonnelle, Claudine Schiff, François Bertucci, Emmanuelle Charafe‐Jauffret and Christophe Ginestier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Yves Toiron

21 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yves Toiron France 13 423 251 236 147 135 21 823
Clara Guerzoni Italy 13 638 1.5× 305 1.2× 203 0.9× 153 1.0× 155 1.1× 18 982
Melanie Janning Germany 14 266 0.6× 98 0.4× 320 1.4× 208 1.4× 45 0.3× 33 746
Kevin Rouault‐Pierre United Kingdom 17 520 1.2× 550 2.2× 335 1.4× 178 1.2× 155 1.1× 37 1.2k
Alberto Rocci Italy 14 417 1.0× 373 1.5× 170 0.7× 87 0.6× 99 0.7× 32 661
Susanne Hipp Germany 15 717 1.7× 207 0.8× 459 1.9× 95 0.6× 378 2.8× 22 1.2k
Aline Mamo Canada 12 474 1.1× 167 0.7× 160 0.7× 92 0.6× 45 0.3× 27 743
Ernesto Díaz-Flores United States 15 558 1.3× 305 1.2× 198 0.8× 84 0.6× 119 0.9× 29 859
Elise R. Bender United States 5 366 0.9× 153 0.6× 413 1.8× 259 1.8× 48 0.4× 5 777
Michael R. Burgess United States 16 370 0.9× 586 2.3× 336 1.4× 35 0.2× 272 2.0× 27 986
Fei Fei United States 14 227 0.5× 229 0.9× 241 1.0× 84 0.6× 113 0.8× 46 654

Countries citing papers authored by Yves Toiron

Since Specialization
Citations

This map shows the geographic impact of Yves Toiron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Toiron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Toiron more than expected).

Fields of papers citing papers by Yves Toiron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Toiron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Toiron. The network helps show where Yves Toiron may publish in the future.

Co-authorship network of co-authors of Yves Toiron

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Toiron. A scholar is included among the top collaborators of Yves Toiron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Toiron. Yves Toiron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lebellec, Loïc, François Bertucci, Emmanuelle Tresch‐Bruneel, et al.. (2018). Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer. 18(1). 963–963. 15 indexed citations
2.
Guérin, Mathilde, Anthony Gonçalvès, Yves Toiron, et al.. (2018). Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget. 9(73). 33762–33777. 16 indexed citations
3.
Mokart, Djamel, Colombe Saillard, Christophe Zemmour, et al.. (2018). Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach. Acta Anaesthesiologica Scandinavica. 62(4). 493–503. 7 indexed citations
4.
5.
6.
Tabouret, Émeline, François Bertucci, Jean‐Yves Pierga, et al.. (2016). MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. 7(14). 18531–18540. 28 indexed citations
7.
8.
Gilabert, Marine, Christophe Ginestier, François Bertucci, et al.. (2014). Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE. 9(8). e104302–e104302. 55 indexed citations
9.
Wicinski, Julien, Olivier Cabaud, Yves Toiron, et al.. (2013). The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. Clinical Cancer Research. 19(23). 6520–6531. 113 indexed citations
10.
Finetti, Pascal, Yves Toiron, Patrice Viens, et al.. (2011). Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment. 132(3). 1035–1047. 14 indexed citations
11.
Gilabert, Marine, Christophe Ginestier, Stéphane Audebert, et al.. (2011). P1-04-07: Poly (ADP-Ribose) Polymerase-1 (PARP-1) Is Overexpressed in Human Breast Cancer Stem Cells: Results from a Proteomic-Based Approach.. Cancer Research. 71(24_Supplement). P1–4. 1 indexed citations
12.
Charafe‐Jauffret, Emmanuelle, François Bertucci, Stéphane Audebert, et al.. (2008). Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Molecular & Cellular Proteomics. 7(8). 1420–1433. 73 indexed citations
13.
Gonçalvès, Anthony, Yves Toiron, Carole Tarpin, et al.. (2007). Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment. Journal of Clinical Oncology. 25(18_suppl). 1010–1010. 1 indexed citations
14.
Ginestier, Christophe, Emmanuelle Charafe‐Jauffret, François Bertucci, et al.. (2002). Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal Of Pathology. 161(4). 1223–1233. 119 indexed citations
15.
Mozziconacci, Julien, Angelika Rosenauer, Audrey Restouin, et al.. (2002). Molecular cytogenetics of the acute promyelocytic leukemia‐derived cell line NB4 and of four all‐trans retinoic acid–resistant subclones. Genes Chromosomes and Cancer. 35(3). 261–270. 14 indexed citations
16.
Gäbert, J, et al.. (1998). Cytogenetic and Molecular Biology for Acute Leukemias at Diagnosis: A Cost/Effectiveness Comparison. Leukemia & lymphoma. 28(3-4). 363–370. 1 indexed citations
17.
Eberlé, Frédéric, Yves Toiron, Jacques Camerlo, et al.. (1995). Persistence of BCR/ABL mRNA-Expressing Bone-Marrow Cells in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission Induced by Interferon-alpha Therapy. Leukemia & lymphoma. 18(1-2). 153–157. 2 indexed citations
18.
Costello, Régis, Marina Lafage, Yves Toiron, et al.. (1995). Philadelphia chromosome‐negative chronic myeloid leukaemia: a report of 14 new cases. British Journal of Haematology. 90(2). 346–352. 31 indexed citations
19.
Rosnet, Olivier, Claudine Schiff, MJ Pébusque, et al.. (1993). Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 82(4). 1110–1119. 27 indexed citations
20.
Rosnet, Olivier, Claudine Schiff, MJ Pébusque, et al.. (1993). Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 82(4). 1110–1119. 273 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clara Guerzoni Breakdown of academic impact, for papers by Melanie Janning Breakdown of academic impact, for papers by Kevin Rouault‐Pierre Breakdown of academic impact, for papers by Alberto Rocci Breakdown of academic impact, for papers by Susanne Hipp Breakdown of academic impact, for papers by Aline Mamo Breakdown of academic impact, for papers by Ernesto Díaz-Flores Breakdown of academic impact, for papers by Elise R. Bender Breakdown of academic impact, for papers by Michael R. Burgess Breakdown of academic impact, for papers by Fei Fei
Rankless by CCL
2026